Jane Street Group LLC increased its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 247.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 106,684 shares of the company's stock after purchasing an additional 75,988 shares during the quarter. Jane Street Group LLC owned 0.19% of Enovis worth $4,593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. grew its position in Enovis by 28.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock worth $76,000 after purchasing an additional 371 shares during the period. Aigen Investment Management LP increased its position in Enovis by 5.1% during the third quarter. Aigen Investment Management LP now owns 8,859 shares of the company's stock valued at $381,000 after acquiring an additional 430 shares during the last quarter. FMR LLC lifted its holdings in Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after acquiring an additional 484 shares during the period. Ridgewood Investments LLC purchased a new position in Enovis in the second quarter worth about $44,000. Finally, State of Alaska Department of Revenue grew its stake in shares of Enovis by 20.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,482 shares of the company's stock valued at $279,000 after purchasing an additional 1,115 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.
Enovis Price Performance
Shares of NYSE:ENOV opened at $45.65 on Wednesday. The company has a market capitalization of $2.55 billion, a P/E ratio of -20.84 and a beta of 1.94. Enovis Co. has a 1-year low of $38.27 and a 1-year high of $65.03. The firm's 50 day simple moving average is $44.38 and its two-hundred day simple moving average is $44.56. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.
Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $505.22 million for the quarter, compared to analysts' expectations of $504.44 million. During the same quarter in the previous year, the company earned $0.56 EPS. Enovis's revenue for the quarter was up 21.0% on a year-over-year basis. Research analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.
Wall Street Analyst Weigh In
ENOV has been the topic of a number of research reports. Needham & Company LLC reissued a "buy" rating and issued a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th. JMP Securities began coverage on shares of Enovis in a research note on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price target on the stock. Finally, Evercore ISI reduced their price objective on Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $67.00.
Check Out Our Latest Analysis on Enovis
About Enovis
(
Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Further Reading
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
